Streetbeat News

Analyst Ratings

NVS

Novartis AG has released positive interim results from its Phase 3 ALIGN study of atrasentan, a drug for IgA nephropathy (IgAN), a major cause of chronic kidney disease. The drug demonstrated a significant reduction in proteinuria in patients with IgAN. Novartis plans to submit an application for possible accelerated approval in the US in 2024. The company's shares are up 1.68% at $93.82.

Portfolio Pulse from Vandana Singh

October 30, 2023 | 3:18 pm

SITE

Stifel analyst W. Andrew Carter maintains a 'Buy' rating on SiteOne Landscape Supply (NYSE:SITE) but has lowered the price target from $185 to $153.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 3:18 pm

PHX

Stifel analyst Derrick Whitfield has maintained a 'Buy' rating on PHX Minerals (NYSE:PHX) but lowered the price target from $5.5 to $5.4.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 3:16 pm

CRM

Salesforce Inc.'s (NYSE:CRM) share price is currently at $198.20, after a 0.83% increase. Over the past month, the stock decreased by 0.82%, but it spiked by 24.01% in the past year. Salesforce's P/E ratio of 122.86 is higher than the Software industry's aggregate P/E ratio of 110.18, indicating that investors expect the company to perform better in the future, but the stock may be overvalued.

Portfolio Pulse from Benzinga Insights

October 30, 2023 | 3:15 pm

OLN

Stifel analyst Vincent Anderson maintains a Buy rating on Olin (NYSE:OLN) but lowers the price target from $66 to $65.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 3:14 pm

LECO

Stifel analyst Nathan Jones has maintained a 'Hold' rating on Lincoln Electric Holdings (NASDAQ:LECO) and lowered the price target from $210 to $192.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 3:13 pm

IPGP

Stifel analyst Ruben Roy has maintained a 'Buy' rating on IPG Photonics (NASDAQ:IPGP) but lowered the price target from $145 to $120.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 3:12 pm

IDXX

Stifel analyst Jonathan Block has maintained a 'Hold' rating on IDEXX Laboratories (NASDAQ:IDXX) and lowered the price target from $500 to $460.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 3:10 pm

HAYW

Stifel analyst W. Andrew Carter maintains a Buy rating on Hayward Holdings (NYSE:HAYW) but has lowered the price target from $16.5 to $15.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 3:08 pm

FND

Stifel analyst John Baugh maintains a 'Buy' rating on Floor & Decor Holdings (NYSE:FND) but has lowered the price target from $120 to $100.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 3:07 pm